CA12 and glioblastoma: Therefore, a new combination therapy, based on a CA XII inhibitor with TMZ may be considered as a potentially viable clinical tool to overcome Pgp-mediated TMZ-resistance in glioblastoma stem cells as well as more effective therapy of the brain tumors [179].